Here are the top 5 biosimilar articles for the week of July 12, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of July 12, 2021.
Number 5: Presentations from the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.
Number 4: In a white paper, the International Generic and Biosimilar Medicines Association (IGBA) described industry dynamics that it said affect market sustainability and patient access.
Number 3: Medicare lost out on over $2 billion in savings as adalimumab biosimilars were sidelined by patent restrictions, said investigators who recommended patent reforms.
Number 2: Bioeq signed a deal with Teva Pharmaceutical Industries to commercialize a ranibizumab biosimilar candidate (FYB201) in the European Union, Canada, Israel, and New Zealand.
Number 1: Biosimilars are launching at significant discounts to reference products and capturing increasing market share, according to a recent Amgen trends report.
To read all of these articles and more, visit centerforbiosimilars.com.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.